Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include Cancer Genomics and Diagnostics, RNA modifications and cancer, RNA Research and Splicing, and Fibroblast Growth Factor Research.
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.
Intratumoral heterogeneity and <i>TERT</i> promoter mutations in progressive/higher-grade meningiomas
Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in <i>ETV6-NTRK3</i> –Positive Acute Myeloid Leukemia
Global Analysis of the RNA-Protein Interaction and RNA Secondary Structure Landscapes of the Arabidopsis Nucleus